Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention

被引:97
作者
Kismet, K
Akay, MT [1 ]
Abbasoglu, O
Ercan, A
机构
[1] Hacettepe Univ, Fac Sci, Dept Biol, TR-06532 Ankara, Turkey
[2] Ankara Res & Training Hosp, Gen Surg Dept 4th, Ankara, Turkey
[3] Hacettepe Univ, Sch Med, Dept Surg, TR-06100 Ankara, Turkey
[4] Hacettepe Univ, Beytepe Med Ctr, TR-06100 Ankara, Turkey
来源
CANCER DETECTION AND PREVENTION | 2004年 / 28卷 / 02期
关键词
celecoxib; non-steroidal anti-inflammatory drugs; cyclooxygenase; chemoprevention;
D O I
10.1016/j.cdp.2003.12.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Non-steroidal anti-inflaminatory drugs (NSAIDs) are the most widely used therapeutic agents in the treatment of pain, inflammation and fever. They may also have a role in the management of cancer prevention, Alzheimer's disease and prophylaxis against cardiovascular disease. These drugs act primarily by inhibiting cyclooxygenase enzyme, which has two isoforms, cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). Selective COX-2 inhibitors provide potent anti-inflammatory and analgesic effects without the side effects of gastric and renal toxicity and inhibition of platelet function. Celecoxib is a potent COX-2 inhibitor being developed for the treatment of rheumatoid arthritis and osteoarthritis. Chemoprevention is the use of pharmacological or natural agents to prevent, suppress, interrupt or reverse the process of carcinogenesis. For this purpose, celecoxib is being used for different cancer types. The effects of NSAIDs on tumor growth remain unclear, but are most likely to be multifocal. In this article, we reviewed COX-2 selectivity, the pharmacological properties of celecoxib, the use of celecoxib for cancer prevention and the mechanisms of chemoprevention. (C) 2004 Published by Elsevier Ltd. on behalf of International Society for Preventive Oncology.
引用
收藏
页码:127 / 142
页数:16
相关论文
共 173 条
[41]  
Fujita T, 1998, CANCER RES, V58, P4823
[42]   Suppressive effects of nimesulide, a selective inhibitor of cyclooxygenase-2, on azoxymethane-induced colon carcinogenesis in mice [J].
Fukutake, M ;
Nakatsugi, S ;
Isoi, T ;
Takahashi, M ;
Ohta, T ;
Mamiya, S ;
Taniguchi, Y ;
Sato, H ;
Fukuda, K ;
Sugimura, T ;
Wakabayashi, K .
CARCINOGENESIS, 1998, 19 (11) :1939-1942
[43]  
FULTON AM, 1985, CANCER RES, V45, P4779
[44]  
FUNKHOUSER EM, 1995, CANCER-AM CANCER SOC, V76, P1116, DOI 10.1002/1097-0142(19951001)76:7<1116::AID-CNCR2820760703>3.0.CO
[45]  
2-I
[46]  
Geis GS, 1999, J RHEUMATOL, V26, P31
[47]  
Graul A., 1997, Drugs of the Future, V22, P711
[48]   REDUCED RISK OF LARGE-BOWEL ADENOMAS AMONG ASPIRIN USERS [J].
GREENBERG, ER ;
BARON, JA ;
FREEMAN, DH ;
MANDEL, JS ;
HAILE, R .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (11) :912-916
[49]   ANALYSIS OF THE MECHANISM OF ULTRAVIOLET-(UV)-B RADIATION-INDUCED PROSTAGLANDIN-E2 SYNTHESIS BY HUMAN EPIDERMOID CARCINOMA-CELLS [J].
GREWE, M ;
TREFZER, U ;
BALLHORN, A ;
GYUFKO, K ;
HENNINGER, H ;
KRUTMANN, J .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1993, 101 (04) :528-531
[50]   COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib [J].
Grösch, S ;
Tegeder, I ;
Niederberger, E ;
Bräutigam, L ;
Geisslinger, G .
FASEB JOURNAL, 2001, 15 (12) :2742-+